Wolfe Research Reiterates Outperform on Eli Lilly, Maintains $1325 Price Target

Benzinga Newsdesk www.benzinga.com Negative 87.1%

Neg 87.1% Neu 0% Pos 0%

Wolfe Research analyst Alexandria Hammond reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1325 price target.